Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (254)
Cancellation by sponsor (91)
Prescription medicine registration (28)
Section 14, TGO91 consent (6)
Australian Public Assessment Report (AusPAR) (1)
Prescription medicine decision summary (1)

Date

2026 (13)
2025 (23)
2024 (13)
2023 (11)
2022 (35)
2021 (68)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (16)
2015 (13)
2014 (7)
2013 (8)
2012 (12)
2011 (5)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (2)
1998 (1)
1996 (3)
1994 (2)
1991 (5)

Search

Sponsor content

381 result(s) found, displaying 231 to 240

CON-TGO91-360 - Juno Pharmaceuticals Pty Ltd

12 October 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
CON-TGO91-363 - Juno Pharmaceuticals Pty Ltd

12 October 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
CON-TGO91-353 - Juno Pharmaceuticals Pty Ltd

9 October 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
CON-TGO91-354 - Juno Pharmaceuticals Pty Ltd

9 October 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
CON-TGO91-358 - Juno Pharmaceuticals Pty Ltd

9 October 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
CON-TGO91-359 - Juno Pharmaceuticals Pty Ltd

9 October 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
ASTRAZENECA NEOSTIGMINE METHYLSULFATE 2.5mg/1mL injection ampoule Cancelled under Section 30(1)(c) of the Act

6 October 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
Neostigmine HHH neostigmine methylsulfate 2.5 mg/1 ml solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

6 October 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
MORPHINE JN morphine hydrochloride trihydrate 100 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
MORPHINE JN morphine hydrochloride trihydrate 50 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.